CADL Stock — Candel Therapeutics Inc.: Cash, EV, Pipeline

Share price

$10.85

Market cap

$830.2M

Cash

$201.6M

Enterprise value

$628.6M

Balance sheet

Cash	$201.6M
Debt	$0.0M
Net cash	$201.6M
Enterprise value	$628.6M
Basic shares	76.1M shares
Fully diluted shares	92.3M shares
Fully diluted market cap	$1,001.4M
Cash per share	$2.65

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CADL daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 15 - Apr 26	aglatimagene besadenovec	Phase 2	Prostate Cancer Patients Treated by Radiotherapy; Prostate Cancer (Adenocarcinoma)	—
Dec 3, 2031 - Jan 14, 2032	Aglatimagene Besadenovec	Phase 3	Non-squamous, Non-Small Cell Lung Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Aglatimagene besadenovec

Phase 3 · Active Modality: off-the-shelf engineered adenovirus immunotherapy (with valacyclovir prodrug)

Aliases CAN-2409

Target HSV-TK

Indications

localized prostate cancer (Phase 3 completed) (Phase 3)
metastatic non-squamous NSCLC (AURORA Phase 3 enrolling) (Phase 3)
NSCLC (Phase 2a) (Phase 2)
pancreatic ductal adenocarcinoma (Phase 2a, paused) (Phase 2)

Status note Prostate Phase 3 completed with topline reported; AURORA pivotal NSCLC Phase 3 enrolling since June 2026; pancreatic PDAC program paused; no discontinuation disclosed.

Linoserpaturev

Phase 1 · Active Modality: oncolytic herpes simplex virus (rQNestin)

Aliases CAN-3110

Partnerships Mass General Brigham/MGB (exclusive worldwide license)

Indications

recurrent high-grade glioma / glioblastoma (Phase 1)

Status note Ongoing investigator-sponsored Phase 1b in recurrent HGG; FDA IND cleared January 2026 supporting potential future randomized Phase 2 dose-regimen study; no discontinuation disclosed.

Alpha-201 Macro1

Preclinical · Active Modality: investigational viral immunotherapy

Target CD47/SIRPa pathway

Indications

solid tumors (Preclinical)

Status note First experimental agent from enLIGHTEN Discovery Platform; preclinical monotherapy activity; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Aglatimagene Besadenovec
Lead indication	Non-squamous, Non-Small Cell Lung Cancer
Lead phase	Phase 3
Active trials	5
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07660094	Phase 3	Recruiting	Sponsor	CADL	—	Non-squamous, Non-Small Cell Lung Cancer	—
NCT01436968	Phase 3	Active, not recruiting	Sponsor	CADL	—	Prostate Cancer	—
NCT07332000	Phase 2	Recruiting	Sponsor	CADL	—	Prostate Cancer Patients Treated by Radiotherapy; Prostate Cancer (Adenocarcinoma)	—
NCT02768363	Phase 2	Active, not recruiting	Sponsor	CADL	—	Prostate Cancer	—
NCT04495153	Phase 2	Active, not recruiting	Sponsor	CADL	—	Non Small Cell Lung Cancer	—
NCT03152318	Phase 1	Active, not recruiting	Collaborator	Dana-Farber Cancer Institute	—	Malignant Glioma of Brain; Astrocytoma; Malignant Astrocytoma	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Candel Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	6,422,018	no change	0.56%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CADL — Candel Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders